	US 12,485,099 B2
	Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
Patrick Mohr, Bad Breisig (DE); René Rietscher, Andernach (DE); René Eifler, Koblenz (DE); and Olga Bourquain, Dürrholz (DE)
Assigned to LTS LOHMANN Therapie-Systeme AG, Andernach (DE)
Filed by LTS LOHMANN Therapie-Systeme AG, Andernach (DE)
Filed on Apr. 22, 2022, as Appl. No. 17/660,313.
Application 17/660,313 is a continuation of application No. 16/470,322, granted, now 11,337,932, previously published as PCT/EP2017/083640, filed on Dec. 19, 2017.
Claims priority of application No. 16205502 (EP), filed on Dec. 20, 2016; and application No. 17178268 (EP), filed on Jun. 28, 2017.
Prior Publication US 2022/0323370 A1, Oct. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/70 (2006.01); A61K 31/407 (2006.01)

CPC A61K 9/7069 (2013.01) [A61K 9/7053 (2013.01); A61K 31/407 (2013.01)]

27 Claims

1. A transdermal therapeutic system for the transdermal administration of asenapine comprising a self-adhesive layer structure comprising a therapeutically effective amount of asenapine, said self-adhesive layer structure comprising:

A) a backing layer;

B) an asenapine-containing layer comprising:

i) asenapine in free base form; and

ii) a polysiloxane or polyisobutylene polymer, wherein the polysiloxane or polyisobutylene polymer comprises more than 50% by weight of the asenapine-containing layer; and

C) optionally an additional skin contact layer; and

wherein the asenapine-containing layer comprises an additional acrylic polymer.